TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01734382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants \< 30 kg) or 8 mg/kg (for participants \>/=30 kg) Q2W/Q3W/Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants \< 30 kg) or 8 mg/kg (for participants \>/=30 kg) Q2W/Q3W/Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants \< 30 kg) or 8 mg/kg (for participants \>/=30 kg) Q2W/Q3W/Q4W.
Study: NCT03119571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initial CCL admission
Description: Admission to the cardiac catheterization lab to evaluated coronary artery disease and if present fix the culprit lesion/lesions

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Initial ICU admission
Description: Evaluate for additional testing and/or procedures
Study: NCT01746602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timophtal sine® 0.5%
Description: Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genteal HA®
Description: Genteal HA® Eye Drops, Novartis, single instillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hylo-Comod®
Description: Hylo-Comod® Eye Drops, Croma-Pharma, single instillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz®
Description: Thealoz® Eye Drops, Thea, France, single instillation
Study: NCT03127787

Intervention type: DIAGNOSTIC_TEST
Intervention: CMV Assay
Description: Molecular diagnostic test to detect CMV
Study: NCT03549507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride lipid-type A microspheres
Description: Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
Study: NCT02945787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spanish-Language Version of the Stop Smoking for Good
Description: Participants in the first arm will receive the Spanish-language version of the Stop Smoking for Good (SS-SP) intervention distributed over 18 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI-Produced Spanish-language Self-help Booklet
Description: Participants in the second arm will receive a single, credible, NCI-produced Spanish-language self-help booklet.
Study: NCT00906997

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immunochemical fecal occult blood test
Description: Biennial, without diet restriction, 1 stool sample. Positive cut-off level: 75 ng/ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Every 10 years, with sedation.
Study: NCT03194490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined intervention group
Description: The combined intervention group received the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).Stretching, cervical passive mobilization, and range of motion: The manual therapy was conducted by a physical therapist who has licensed from the California Board of Physical Therapy. The cervical passive mobilization were selected by the physical therapist based on the participant's condition. Stretching techniques were performed in the combined intervention group for 30 seconds and repeated 3 times twice a week in the following order on the following muscles: anterior, middle and posterior scalene, upper fibers of trapezius, pectoralis minor and interspinous muscles .AROM Exercise were performed 10 repetitions 3-4 times daily. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The standard intervention
Description: The standard intervention group will receive cervical mobilization and home program (ROM exercises).~Cervical mobilization and range of motion: The manual therapy was conducted by a physical therapist who has experience in manual therapy and is licensed from the California Board of Physical Therapy. The manual therapy intervention will consist of Passive Accessory Intervertebral Movements (PAIVMs). The nature of PAIVMs techniques was selected by the physical therapist based on the participant's condition.~Active Cervical Range of Motion Exercises (ACROM) were performed 10 repetitions 3-4 times daily. Subjects were advised to maintain their usual activity within the limits of pain. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral .
Study: NCT04086875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Participate in focus group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive text messages

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00880165

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure apparatus
Description: Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure apparatus
Description: Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.
Study: NCT01473927

Intervention type: OTHER
Intervention: Endoscopy
Description: Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.

Intervention type: OTHER
Intervention: Endoscopy
Description: Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
Study: NCT05547022

Intervention type: PROCEDURE
Intervention: Endovascular revascularisation
Description: Peripheral vascular angioplasty or stenting
Study: NCT03457233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: 1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: 1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: 1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNRH antagonist
Description: cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNRH antagonist
Description: cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNRH antagonist
Description: cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin Chorimon
Description: 10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin Chorimon
Description: 10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin Chorimon
Description: 10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natural progesterone
Description: 400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natural progesterone
Description: 400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natural progesterone
Description: 400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing
Study: NCT00603421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24 hour phone line
Description: 24 hour phone line is available as soon as the patient himself feels necessary. This phone line is supported by professionals of mental health, all specialised in borderline personality disorder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: Treatment as usual
Study: NCT00488878

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Patients' residual tissue samples are collected

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study: NCT03303703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RENEwS
Description: The intervention participants will meet with a trained interventionist for five 60-minute sessions as a group (two groups of five participants each). In the sessions time will be divided between didactic presentation of material, active practicing of techniques, group work focused on case studies, and worksheets for further practice at home. Topics covered within the intervention include emotional awareness, balancing emotional and physical wellbeing, selecting and implementing emotion regulation strategies (such as situation selections, mindfulness, engagement/avoidance, reappraisal, and emotional sharing), and emotional monitoring.
Study: NCT03112590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-γ)
Description: Phase 1: IFN-γ 50 or 75 mcg/m\^2 SQ x 3 days/week for 12 weeks. Phase 2: IFN-γ at Recommended Phase II Dose (RP2D) subcutaneously (SQ) x 3 days/week, for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Phase 1 and Phase 2: Paclitaxel 80 mg/m\^2/week, for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Phase 1 and Phase 2: Trastuzumab 8 mg/kg intravenous (IV) loading dose on cycle 1/day 1 (C1D1), followed by 6 mg/kg on subsequent cycles every 3 weeks, for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Phase 1 and Phase 2: Pertuzumab 840 mg IV loading dose on C1D1, followed by 420 mg on subsequent cycles every 3 weeks, for 12 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Therapy Surgery
Description: Phase 2: Participants will be assessed for surgery following the fourth cycle of study therapy (or earlier if study treatment is cancelled due to unmanageable side effects).
Study: NCT00924417

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine Care
Description: Parent given placebo intervention that entails brief information about what is routine care for intravenous line placement in the emergency department

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Parent given brief information about the cognitive behavioral technique known as distraction. Parent and child then given 3 distraction toys/tools to assist with peripheral intravenous line placement.
Study: NCT02457585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remicade (anti tumor necrosis factor inhibitor)
Description: single arm:remicade treatment group
Study: NCT04572802

Intervention type: PROCEDURE
Intervention: Coronary angiography
Description: Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus

Intervention type: PROCEDURE
Intervention: Coronary angiography
Description: Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus

Intervention type: PROCEDURE
Intervention: Coronary angiography
Description: Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus

Intervention type: PROCEDURE
Intervention: Coronary angiography
Description: Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus
Study: NCT01854944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 1mg to 4mg
Study: NCT04620707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RGS based training and monitoring
Description: The RGS treatment will consist in a variable number of sessions per week of RGS-based training. Each session consists of cognitive and motor training involving reaching, grasping, placing virtual objects. The duration of the training period will be variable. Patients will use the RGS@Clinic from admission to discharge, and will have the RGS@Home during the first 3 months of the outpatient stage after recruitment. After this period of time, the patient will be evaluated by clinicians and the RGS@Home system will be collected. The RGS-Wear will be kept by the patient also during the follow-up period, up to 1 year post-recruitment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy as usual
Description: The patients will follow treatment as usual, including conventional rehabilitation and physical therapy when corresponding. The exact treatment that the patients will receive will depend on the local medical guidelines.
Study: NCT00323869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nucleoside analog

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Alkylating agent
Study: NCT01040078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5ug H1N1 Influenza vaccine
Description: 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15ug H1N1 vaccine
Description: 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: seasonal influenza vaccine
Description: 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
Study: NCT02037581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early detection and Integrated Care
Description: Patients receive integrated care including therapeutic Assertive Community Treatment (TACT)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Standard care as being offered by private psychiatrists
Study: NCT03845374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyper-CL™ lens
Description: Use of the Hyper-CL™
Study: NCT00336583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin, 130 mg per square meter, on day 1
Study: NCT00399672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon injections and ribavirin
Description: Weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon injections and ribavirin
Description: Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
Study: NCT03624530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor (TKIs)
Description: TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of TKI was 180 days.
Study: NCT02732522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal misoprostol
Study: NCT04258137

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Description: Liquid biopsy will be performed at cycle 1 day 1 and cycle 2 day of each line of systemic treatment, at each tumor evaluation by Imaging and at confirmation of progression

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Description: Liquid biopsy will be performed at cycle 1 day 1 and cycle 2 day of each line of systemic treatment, at each tumor evaluation by Imaging and at confirmation of progression
Study: NCT03249389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
Study: NCT01698281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEZS-108
Description: AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle. Allowed delay of re-treatment: up to 2 weeks.~Dose reduction: to 210 mg/m2 and 160 mg/m2, if dose limiting toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCCC
Description: commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).~Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.~Related to PLD: Per notification from EMA (dated 22-Nov-2011) no new patients should be started on treatment with Caelyx until further notice. Accordingly, this drug may be selected as SSCC treatment option only after such written notice is available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone.
Study: NCT04048785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention
Description: The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
Study: NCT02097927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mango-flavour beverage
Description: The study will be a 3-way crossover design: it will assess the impact of a high-energy, sensory-enhanced beverage on energy intake through ad libitum food consumption and subjective feeling of appetite using visual analogue scales (VAS) compared to 2 control beverages following repeated exposures. Each participant will consume each beverage 10 times. This includes 2 satiety-testing sessions on site at Leatherhead Food Research, and 8 occasions consuming the product as a mid-morning snack during the participants' normal routine. Each participant will attend the Nutrition Unit on 6 different occasions before and after repeated exposures to the beverages at home. There will be a two-week washout period in which none of the beverages are consumed between the different beverage manipulations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mango-flavour beverage
Description: The study will be a 3-way crossover design: it will assess the impact of a high-energy, sensory-enhanced beverage on energy intake through ad libitum food consumption and subjective feeling of appetite using visual analogue scales (VAS) compared to 2 control beverages following repeated exposures. Each participant will consume each beverage 10 times. This includes 2 satiety-testing sessions on site at Leatherhead Food Research, and 8 occasions consuming the product as a mid-morning snack during the participants' normal routine. Each participant will attend the Nutrition Unit on 6 different occasions before and after repeated exposures to the beverages at home. There will be a two-week washout period in which none of the beverages are consumed between the different beverage manipulations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mango-flavour beverage
Description: The study will be a 3-way crossover design: it will assess the impact of a high-energy, sensory-enhanced beverage on energy intake through ad libitum food consumption and subjective feeling of appetite using visual analogue scales (VAS) compared to 2 control beverages following repeated exposures. Each participant will consume each beverage 10 times. This includes 2 satiety-testing sessions on site at Leatherhead Food Research, and 8 occasions consuming the product as a mid-morning snack during the participants' normal routine. Each participant will attend the Nutrition Unit on 6 different occasions before and after repeated exposures to the beverages at home. There will be a two-week washout period in which none of the beverages are consumed between the different beverage manipulations.
Study: NCT01527357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrocaps
Description: Human fibrinogen and thrombin powder, for topical administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gelatin sponge
Description: Absorbable gelatin sponge for topical administration.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge
Description: Absorbable gelatin sponge for topical administration.